Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by StockNews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday.

Other equities research analysts have also issued reports about the company. Royal Bank of Canada reiterated an “outperform” rating and set a $310.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Scotiabank dropped their price target on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating for the company in a research report on Friday, February 14th. HC Wainwright upped their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Needham & Company LLC restated a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. Finally, William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $310.22.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $283.34 on Friday. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The stock has a 50 day moving average of $257.16 and a two-hundred day moving average of $259.69. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a market cap of $36.68 billion, a P/E ratio of -130.57 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,234 shares of company stock worth $19,958,097. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ALNY. Larson Financial Group LLC raised its position in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares in the last quarter. Park Square Financial Group LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $28,000. R Squared Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $33,000. OFI Invest Asset Management purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $35,000. Finally, Colonial Trust Co SC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $35,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.